Verona Pharma Plc has agreed to grant exclusive rights to Nuance Pharma Ltd of Shanghai, China for its respiratory treatment ensifentrine in exchange for an upfront payment of $25 million in cash and other considerations. The rights relate to the development and commercialisation of ensifentrine in mainland China and adjacent territories. Ensifentrine is an investigational therapy, currently in a global Phase 3 programme for the treatment of chronic obstructive pulmonary disease (COPD). Late-stage clinical trials are currently underway at sites in the US, Europe and South Korea.
